Prevalence of anti-JC - virus among patients suffering from multiple sclerosis in Kazakhstan

被引：0
|
作者：
Sharapkhanova, A. [1 ]
Kamenova, S. [1 ]
Kuzhybayeva, K. [1 ]
机构：
[1] JSC Natl Med Univ, Dept Nervous Dis, Course Neurosurg, Alma Ata, Kazakhstan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1452
引用
收藏
页码：809 / 810
页数：2
相关论文
共 50 条
  • [21] Anti-JC Virus Antibodies in a Large German Natalizumab-Treated Multiple Sclerosis Cohort
    Chan, Andrew
    Trampe, Anne-Kathrin
    Hemmelmann, Claudia
    Stroet, Anke
    Haghikia, Aiden
    Hellwig, Kerstin
    Wiendl, Heinz
    Goelz, Susan
    Ziegler, Andreas
    Gold, Ralf
    NEUROLOGY, 2012, 78
  • [22] Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence
    Koolaji, Sogol
    Allahabadi, Narges Sistany
    Ahmadi, Arash
    Eskandarieh, Sharareh
    Moghadasi, Abdorreza Naser
    Azimi, Amir Reza
    Sahraian, Mohammad Ali
    JOURNAL OF NEUROVIROLOGY, 2018, 24 (05) : 570 - 576
  • [23] Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence
    Sogol Koolaji
    Narges Sistany Allahabadi
    Arash Ahmadi
    Sharareh Eskandarieh
    Abdorreza Naser Moghadasi
    Amir Reza Azimi
    Mohammad Ali Sahraian
    Journal of NeuroVirology, 2018, 24 : 570 - 576
  • [24] Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial
    Bozic, C.
    Subramanyam, M.
    Paes, D.
    Richman, S.
    Plavina, T.
    Zhang, A.
    Ticho, B.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 371 - 372
  • [25] Prevalence of anti-JC virus antibodies in a cohort of 1'200 natalizumab-treated MS patients
    Radji, F.
    Outteryck, O.
    Zephir, H.
    Ongagna, J. C.
    Brochet, B.
    Ouallet, J. C.
    Rumbach, L.
    Lebrun-Frenay, C.
    Debouverie, M.
    Pittion, S.
    Laplaud, D.
    Wiertlewski, S.
    Cabre, P.
    Confavreux, C.
    Vukusic, S.
    Pelletier, J.
    Audouin, B.
    Defer, G.
    Derache, N.
    Camu, W.
    Thouvenot, E.
    Tourbah, A.
    Labauge, P.
    Moreau, T.
    Fromont, A.
    Castelnovo, G.
    Clavelou, P.
    Casez, O.
    Hautecoeur, P.
    Papeix, C.
    Couturier, N.
    Viala, F.
    Liblau, R.
    Clanet, M.
    De Seze, J.
    Vermersch, P.
    Brassat, D.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S216 - S216
  • [26] Anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis treated with natalizumab
    Krieger, S.
    Sinks, S.
    Huang, F.
    Wen, G.
    Steverson, J.
    Piccinini, L. A.
    Kalina, T. J.
    White, K.
    Avila, R. L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 980 - 981
  • [27] Anti-JC Virus Seronegative African American Patients with Early Multiple Sclerosis Treated with Natalizumab in STRIVE: A Post-hoc Analysis
    Perumal, J.
    Fox, R. J.
    Balcer, L.
    Balabanov, R.
    Galetta, S.
    Su, R.
    Campagnolo, D.
    Hotermans, C.
    Lee, L.
    Rutledge, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 38 - 39
  • [28] An alternative assay to assess the anti-JC virus status in MS patients
    Warnke, C.
    Pawlita, M.
    Dehmel, T.
    Hartung, H. -P.
    Wiendl, H.
    Kieseier, B. C.
    Adams, O.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 371 - 371
  • [29] Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial
    Bozic, C.
    Subramanyam, M.
    Richman, S.
    Plavina, T.
    Zhang, A.
    Ticho, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (02) : 299 - 304
  • [30] 10 years of Natalizumab treatment in a multiple sclerosis center in Brazil: experience beyond 24 months in Anti-JC virus antibodies positive patients
    Thomaz, R. B.
    Correa, M. F. A.
    Soares, H. R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 557 - 558
12345